| Nomenclature | GPR31 | GPR32 | GPR33 | GPR34 |
| HGNC, UniProt | GPR31, O00270 | GPR32, O75388 | GPR33, Q49SQ1 | GPR34, Q9UPC5 |
| Potency order of endogenous ligands | – | resolvin D1>LXA 4 | – | – |
| Endogenous agonists | 12S‐HETE [700] – Mouse | resolvin D1 [1052], LXA 4 [1052] | – | lysophosphatidylserine [1008, 1891] |
| Labelled ligands | – | [3 H]resolvin D1 (Agonist) [1052] | – | – |
| Comments | See [414] for discussion of pairing. | resolvin D1 has been demonstrated to activate GPR32 in two publications [331, 1052]. The pairing was not replicated in a recent study based on arrestin recruitment [1854]. GPR32 is a pseudogene in mice and rats. See reviews [258] and [414]. | GPR33 is a pseudogene in most individuals, containing a premature stop codon within the coding sequence of the second intracellular loop [1696]. | Lysophosphatidylserine has been reported to be a ligand of GPR34 in several publications, but the pairing was not replicated in a recent study based on arrestin recruitment [1854]. Fails to respond to a variety of lipid‐derived agents [2182]. Gene disruption results in an enhanced immune response [1168]. Characterization of agonists at this receptor is discussed in [859] and [414]. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.